The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.
about
A multi-level multi-scale approach to study essential genes in Mycobacterium tuberculosisA web server for predicting inhibitors against bacterial target GlmU proteinStructural and functional analysis of the transcriptional regulator Rv3066 of Mycobacterium tuberculosisCrystal structure of the transcriptional regulator Rv1219c ofMycobacterium tuberculosisCrystal Structure of the Transcriptional Regulator Rv0678 of Mycobacterium tuberculosisA monoacylglycerol lipase from Mycobacterium smegmatis Involved in bacterial cell interactionGenHtr: a tool for comparative assessment of genetic heterogeneity in microbial genomes generated by massive short-read sequencing.Epidemiology and treatment of multidrug resistant tuberculosis6-Oxo and 6-thio purine analogs as antimycobacterial agents.Identification of residues involved in substrate specificity and cytotoxicity of two closely related cutinases from Mycobacterium tuberculosisEvaluation of tuberculosis infection control measures implemented at primary health care facilities in Kwazulu-Natal province of South Africa.Synthesis, biological evaluation and 2D-QSAR study of halophenyl bis-hydrazones as antimicrobial and antitubercular agents.InbR, a TetR family regulator, binds with isoniazid and influences multidrug resistance in Mycobacterium bovis BCG.Structural Basis for the Regulation of the MmpL Transporters of Mycobacterium tuberculosis.Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.New Conjugates of Quinoxaline as Potent Antitubercular and Antibacterial AgentsEfficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxideThe Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics.Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.Synthesis of deoxygenated alpha(1-->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosisMycobacterium tuberculosis: drug resistance and future perspectives.Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections.Role of glycans and glycoproteins in disease development by Mycobacterium tuberculosis.Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages.Design, synthesis and antitubercular activity of certain nicotinic Acid hydrazides.Antimycobacterial activity of cyclic dipeptides isolated from Bacillus sp. N strain associated with entomopathogenic nematode.Maximizing bactericidal activity with combinations of bioreduced drugs.Importance of improved TB diagnostics in addressing the extensively drug-resistant TB crisis.Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease.Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design.Multidrug-resistant tuberculosis among patients in Baja California, Mexico, and Hispanic patients in CaliforniaCancer in Africa: a preventable public health crisisSynthesis of New Fluorine Substituted Heterocyclic Nitrogen Systems Derived fromp-Aminosalicylic Acid as Antimycobacterial AgentsSynthesis of Substituted Thioureas and Their Sulfur Heterocyclic Systems ofp-Amino Salicylic Acid as Antimycobacterial Agents
P2860
Q21202770-DA0C1EB9-6138-40EF-B24F-FDE54365BBD2Q27496633-EFFA84E0-DD82-41D2-A445-AC0B1A2150ADQ27670866-FB531641-3CFB-47B0-91CE-295B6FC38F0DQ27681336-9A713B15-7553-43C6-9384-15B4B32741ACQ27683409-AC25635A-16DE-45CF-AA8A-77E8049A0621Q28501842-444FA920-8242-49C4-A992-976730EA9FB6Q30990230-EB8335EA-7F4A-42AD-8061-FF58469C1EE7Q33710690-36E25B56-7751-4DCD-AA64-130EEC3E6AAAQ34597039-D1A24A26-0BAE-4E72-95FA-9F46E8A08109Q34812287-13C39AB4-D2FA-4A13-A074-CA94141C567DQ35205113-1ECBCAC5-4923-4396-880B-05FAFCBCD4BFQ35585730-E65EE395-D299-4A80-8982-501C6AC24339Q36044723-C03B1F3E-B00A-4D04-9B28-44EC5AA52EAFQ36301363-1F414686-3775-49D7-9CDF-F81C6A3D49DEQ36420040-E520E030-FCB0-4478-A639-2A6D18FB5A72Q36712843-472560BE-3EA7-41E7-AFC4-48DFE6EFB168Q36870749-4F258CB2-9EBA-408B-BE76-C91550821030Q36953414-4F3AED86-21A2-4B30-BD0D-2E4025424812Q37107614-7093A5B9-998F-474D-86C5-C2AADEFAE896Q37119027-78045990-C3DF-452C-B79F-5E5B8E5C7364Q37144919-2D648FEA-4A42-40AE-9643-C241FAADDE93Q37254836-C6D141D2-B1C3-44BB-8885-12AEFC4F74D6Q37506524-15C12E9A-398F-4469-A6D5-0AC835A4FCA6Q37727181-90F3BDE1-1E3B-4712-80F1-0B809EB0EE85Q37983107-93D7E732-CAAE-423D-8A10-25A281AFBAB3Q38016157-86B3571A-CAAA-48D8-BB72-21F015999E81Q38873225-58E59CF0-C711-40FC-B749-AF8AADEA25A4Q39094346-075C83A7-2F1E-4B56-A982-0CB8171D6A4AQ39769351-13412EB9-14A7-444F-9323-828B31FEBC57Q40066961-A44476BC-A62E-44E3-8CB9-C300E6C1FF46Q40776051-3B50E8BB-8B69-4B48-AF8A-EA6612B9B0E1Q52616818-1EB7B11A-68A7-44F1-9D01-699BE4001F30Q57079776-CBD9A3D3-509B-4BB1-A6F8-C5974D2EE8BBQ57251784-169A530C-4BD1-49C4-A7B8-4B138238B020Q59010578-207C7DD0-E3A0-4E1A-BBF8-BE35E125D5B5Q59011039-1DB48EFD-4854-4311-A36E-90D5CDA6B019
P2860
The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The evolution of extensively d ...... and issues for global control.
@en
type
label
The evolution of extensively d ...... and issues for global control.
@en
prefLabel
The evolution of extensively d ...... and issues for global control.
@en
P2093
P1476
The evolution of extensively d ...... and issues for global control.
@en
P2093
Barbara E Laughon
Kevin V Plumley
Robert C Goldman
P356
10.2174/187152607781001844
P577
2007-06-01T00:00:00Z